Gemcitabine HCl (Gemcitabine HCl) Patent Expiration, LOE Window & CMS Spending

Gemcitabine HCl (Gemcitabine HCl) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 14 AB generics, $4.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$4.5M
2024 Medicare Part D Spend$533K
2024 Medicaid Spend$4.0M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 28.4% 2-yr change)